GlassScriptPhysician profile
Winde R Chambers
NPI 1407952534
$9,476.87
in general payments reported to CMS, 2019-2025
30 companies · $2,078 in 2025
The $2,078 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,411 · 2022: $1,156 · 2023: $1,982 · 2024: $2,850 · 2025: $2,078.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,899 · Education: $10.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,899.08 |
| Education | $10.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,087.83 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,704.25 | 2021-2025 | Xifaxan, Trulance, Relistor |
| Janssen Biotech, INC. | $763.42 | 2021-2025 | Tremfya, Stelara |
| Ardelyx, INC. | $566.22 | 2023-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $542.95 | 2021-2025 | Entyvio, Gattex |
| Phathom Pharmaceuticals, INC. | $445.42 | 2024-2025 | Voquezna |
| Genzyme Corporation | $416.32 | 2022-2025 | |
| Evoke Pharma, INC. | $365.44 | 2021-2025 | |
| Pfizer INC. | $305.17 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $263.12 | 2021-2024 | Dificid |
| Fujifilm Healthcare Americas Corporation | $250.00 | 2024 | Utaswako Afp-L3 |
| Qol Medical, LLC | $229.95 | 2023-2025 | Sucraid, Sucraid |
| Lilly USA, LLC | $207.16 | 2024-2025 | Omvoh |
| E.R. Squibb & Sons, L.L.C. | $201.46 | 2023-2024 | Zeposia |
| Ironwood Pharmaceuticals, INC | $139.86 | 2022-2024 | Linzess |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $139.00 | 2025 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $138.84 | 2023 | Cyltezo |
| Aimmune Therapeutics, INC. | $138.44 | 2024 | |
| Redhill Biopharma INC. | $130.02 | 2021-2023 | Aemcolo, Movantik, Talicia |
| Gilead Sciences, INC. | $101.07 | 2025 | |
| Madrigal Pharmaceuticals | $66.87 | 2025 | Rezdiffra |
| Braintree Laboratories, INC. | $50.76 | 2021-2024 | Sutab, Suflave |
| Celltrion USA INC. | $44.73 | 2025 | Vegzelma |
| Celgene Corporation | $39.79 | 2023-2024 | Zeposia |
| Ferring Pharmaceuticals INC. | $33.97 | 2023 | Rebyota |
| Intercept Pharmaceuticals, INC. | $30.08 | 2023-2024 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $26.27 | 2023 | Dupixent |
| Ipsen Biopharmaceuticals, INC | $20.44 | 2025 | Iqirvo |
| Nestle Healthcare Nutrition INC. | $17.54 | 2023 | |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Winde Chambers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.